Established Pharmaceuticals — Selling, general, and administrative
Abbott Established Pharmaceuticals — Selling, general, and administrative decreased by 0.3% to $376.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 7.1%, from $351.00M to $376.00M. Over 3 years (FY 2022 to FY 2025), Established Pharmaceuticals — Selling, general, and administrative shows relatively stable performance with a 2.0% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
A lower ratio of SG&A to sales suggests improved operational efficiency and better cost management.
Detailed definition
This metric includes all operating expenses related to the sales, marketing, and general administration of the establish...
Peer comparison
Standard SG&A expense reporting for business segments across all industries.
abt_segment_established_pharmaceuticals_selling_general_and_administrativeHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $343.00M | $343.00M | $343.00M | $343.00M | $332.50M | $332.50M | $332.50M | $332.50M | $334.00M | $344.00M | $336.00M | $327.00M | $351.00M | $363.00M | $364.00M | $377.00M | $376.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -3.1% | +0.0% | +0.0% | +0.0% | +0.5% | +3.0% | -2.3% | -2.7% | +7.3% | +3.4% | +0.3% | +3.6% | -0.3% |
| YoY Change | — | — | — | — | -3.1% | -3.1% | -3.1% | -3.1% | +0.5% | +3.5% | +1.1% | -1.7% | +5.1% | +5.5% | +8.3% | +15.3% | +7.1% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Abbott's established pharmaceuticals — selling, general, and administrative?
- Abbott (ABT) reported established pharmaceuticals — selling, general, and administrative of $376.00M in Q1 2026.
- How has Abbott's established pharmaceuticals — selling, general, and administrative changed year-over-year?
- Abbott's established pharmaceuticals — selling, general, and administrative increased by 7.1% year-over-year, from $351.00M to $376.00M.
- What is the long-term trend for Abbott's established pharmaceuticals — selling, general, and administrative?
- Over 3 years (2022 to 2025), Abbott's established pharmaceuticals — selling, general, and administrative has grown at a 2.0% compound annual growth rate (CAGR), from $1.37B to $1.46B.
- What does established pharmaceuticals — selling, general, and administrative mean?
- The total operating costs for sales, marketing, and administration within the segment.